Podcast episode 30 (in German)
Rapamycin: mTOR, Easter Island and the star of longevity research
August 2, 2026
The molecule that extends life in animal experiments more reliably than any other comes from a soil sample collected on Easter Island in 1964. Rapamycin is an approved drug, and longevity research sees an entirely new role for it.
What it is about
Rapamycin, also called sirolimus, is produced by a bacterium from the soil of Easter Island and is named after the island’s own name, Rapa Nui. It is approved to dampen the immune system in organ transplant recipients. The episode explains how it became the namesake of the cellular switch mTOR: when mTOR is active, the cell builds; when it is throttled, the cell cleans up and recycles, a process called autophagy that fasting also triggers. It then turns to the animal data, the first human studies, the Dog Aging Project and the question of how an immunosuppressant becomes a longevity candidate. The answer lies in the pattern: low and pulsed instead of high and daily. What remains is a real drug whose longevity benefit in humans is still open.
Key points
- In 2009, Harrison and colleagues showed in Nature that rapamycin extends the life of mice, by roughly 9 percent in males and 14 percent in females.
- The mice were already old when treatment began, equivalent to about 60 human years; the effect was confirmed in independent labs and also in worms, flies and yeast.
- The placebo-controlled PEARL study in healthy adults, with results published in 2024, showed good tolerability of low, intermittent doses and, among other things, more lean mass in women.
- In a study with the related drug everolimus, published in Science Translational Medicine in 2014, older people treated with a low dose responded about 20 percent better to the flu vaccine.
- Low, pulsed dosing mainly hits the clean-up complex mTORC1 and largely leaves mTORC2 alone, to which many of the unwanted effects of continuous dosing are linked.
- In the Dog Aging Project, first smaller investigations showed signs of better heart function in older dogs; the large results are still pending, as of August 2026.
Where the data stop
Life extension is well supported in animal experiments, not in humans; that would take decades. PEARL shows tolerability and cautious signals, not proof of a longer life. Under high daily doses, as in transplant recipients, mouth ulcers, elevated blood lipids, delayed wound healing and impaired glucose metabolism occur; at low doses, studies describe milder profiles, most commonly mild gastrointestinal complaints or mouth ulcers.
Rapamycin is prescription-only; longevity use is off-label. Anyone considering this route belongs under medical supervision with regular checks of blood count, blood lipids and blood glucose. The foundation remains the same: fasting, exercise, sleep and diet throttle mTOR without a prescription, and a drug does not replace a lifestyle.
Listen (in German)
Listen on Spotify Listen on Apple Podcasts Listen on Amazon Music
Published on August 2, 2026.
The topic in the database
- One of the most exciting longevity molecules of all: approved as sirolimus and the drug with the strongest life-extension data in mammalsRapamycin (Sirolimus)
All episodes in the app (German)
Information only, not medical advice and not a usage or dosage recommendation. Prescription-only and unapproved substances belong in the hands of a physician. Last updated: 2026-10-09.